Trial · NCT07883746
Remote Digital Assessments for Cognitive Disorders
NCT07883746, Not yet recruiting, Centre for Addiction and Mental Health
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Remote Digital Assessments for Cognitive Disorders. Trials, record NCT07883746. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883746
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Remote Digital Assessments for Cognitive Disorders
- NCT number
- NCT07883746
- Status
- Not yet recruiting
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Centre for Addiction and Mental Health
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant Completion Rate | Baseline through 12 months | Proportion of enrolled participants who complete the baseline assessment and at least one follow-up assessment at 6 or 12 months. A completion rate of at least 80% is the prespecified feasibility benchmark. |
| Primary | System Usability Scale (SUS) Score | Baseline, 6 months, and 12 months | Usability of MonitorCog-AI will be measured using the 10-item System Usability Scale (SUS). Item responses are scored and transformed to a total score ranging from 0 to 100, with higher scores indicating better perceived system usability. Total scores will be summarized at baseline, 6 months, and 12 months. |
| Primary | Participant Acceptability of MonitorCog-AI | Baseline, 6 months, and 12 months | Participant acceptability will be measured as the percentage of participants reporting an overall satisfaction rating of 4 or 5 on a study-specific 5-point satisfaction scale. Scores range from 1 to 5, with higher scores indicating greater satisfaction. At least 75% reporting a rating of 4 or higher is the prespecified acceptability benchmark. |
| Primary | User Burden Scale (UBS) Score | Baseline, 6 months, and 12 months | Participant-perceived burden of completing MonitorCog-AI will be measured using the 20-item User Burden Scale (UBS), which assesses difficulty of use, physical burden, time and social burden, mental and emotional burden, privacy burden, and financial burden. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 80, with higher scores indicating greater perceived burden. Total scores will be summarized at baseline, 6 months, and 12 months. |
| Secondary | Diagnostic Performance of MonitorCog-AI | Baseline | Diagnostic performance of the AI-based multimodal model will be evaluated for healthy controls versus mild cognitive impairment (MCI), healthy controls versus Alzheimer's disease (AD), and MCI versus AD. Performance will be summarized using area under the receiver operating characteristic curve (AUC) with 95% confidence intervals, sensitivity, specificity, and calibration measures where estimable. |
| Secondary | Incremental Performance of the Multimodal AI Model | Baseline | The diagnostic performance of the multimodal AI model will be compared with the best-performing single-modality model for each diagnostic contrast. Differences in area under the receiver operating characteristic curve (AUC) will be estimated with 95% confidence intervals. |
| Other | Change From Baseline in SATURN Total Score at 6 Months | Baseline and 6 months | Digital cognitive performance will be assessed using the Self-Administered Tasks Uncovering Risk of Neurodegeneration (SATURN). Total scores range from 0 to 30 points, with higher scores indicating better cognitive performance. Change from baseline will be calculated as the 6-month total score minus the baseline total score. The possible change ranges from -30 to +30 points. |
| Other | Change From Baseline in SATURN Total Score at 12 Months | Baseline and 12 months | Digital cognitive performance will be assessed using the Self-Administered Tasks Uncovering Risk of Neurodegeneration (SATURN). Total scores range from 0 to 30 points, with higher scores indicating better cognitive performance. Change from baseline will be calculated as the 12-month total score minus the baseline total score. The possible change ranges from -30 to +30 points. |
| Other | Correlation Between Changes in SATURN and Montreal Cognitive Assessment Scores at 6 Months | Baseline and 6 months | The correlation between change from baseline to 6 months in digital cognition, measured using the Self-Administered Tasks Uncovering Risk of Neurodegeneration (SATURN) total score, and clinical cognition, measured using the Montreal Cognitive Assessment (MoCA) total score, will be estimated using Spearman's rank correlation coefficient (rho). Both instruments have total scores ranging from 0 to 30 points, with higher scores indicating better cognitive performance. Change scores are calculated as 6-month scores minus baseline scores. Spearman's rho is unitless and ranges from -1 to +1. |
| Other | Correlation Between Changes in SATURN and Montreal Cognitive Assessment Scores at 12 Months | Baseline and 12 months | The correlation between change from baseline to 12 months in digital cognition, measured using the Self-Administered Tasks Uncovering Risk of Neurodegeneration (SATURN) total score, and clinical cognition, measured using the Montreal Cognitive Assessment (MoCA) total score, will be estimated using Spearman's rank correlation coefficient (rho). Both instruments have total scores ranging from 0 to 30 points, with higher scores indicating better cognitive performance. Change scores are calculated as 12-month scores minus baseline scores. Spearman's rho is unitless and ranges from -1 to +1. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883746
GET https://conductscience.org/api/trials/v1/NCT07883746/registered